Eli Lilly and Company and San Diego-based Strateos, Inc. unveiled a new robotic laboratory designed to accelerate the drug discovery process. The Lilly Life Sciences Studio lab was conceptualized and designed by Lilly as part of a $90 million investment made in 2017 to expand Lilly's research footprint in San Diego. Strateos will utilize their robotic cloud platform to enable the access of this remote-controlled lab to other drug discovery companies and research scientists through its secure cloud-based platform as part of the collaboration.
Scientists anywhere on the planet can now test, synthesize, and optimize drug discovery compounds without needing to set foot in the lab themselves! The new resource can be accessed by web browser from anywhere in the world via a robotic cloud-based platform and is open to anyone.
The lab is 11,500 square feet, located in the Lilly Biotechnology Center in San Diego and has space for over 100 instruments and storage of over 5 million compounds. However, the equipment can be utilized by anyone, located anywhere in the world with an internet connection. Operated on the Strateos Robotic Cloud Lab platform, scientists are able to remotely control their experiments on the secure web-based interface.
“Lilly and Strateos have long histories of leadership in lab automation and we are pleased to combine our collective expertise to expanded access to this facility via the Strateos Robotic Cloud Lab platform. This laboratory represents the next evolution in drug discovery as we close the loop of synthesis and testing,” commented Mark Fischer-Colbrie, CEO at Strateos.